Research Article

Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis

Table 3

Circulating biomarkers in patients and in the control group.

ParametersControl group () Me (25, 75)Group 1 without HF () Me (25, 75)Group 2 HFpEF () Me (25, 75)Group 3 HFmrEF () Me (25, 75) for gr. 1, 2, and 3 for gr. 1 vs. 2 for gr. 1 vs. 3 for gr. 2 vs. 3

Nt-proBNP pg/mlā€”52.4 (14.5, 104.3)133.6 (78.5, 198.5)162.5 (134.6, 216.7)0.0050.0050.0030.03
sST-2, ng/ml18.3 (15.6, 21.2)19.2 (16.2, 26.3)19.9 (12.9, 40.7)19.6 (13.8, 37.1)0.970.890.770.28
Galectin-3, ng/ml5.7+ (4.9, 6.3)8.6 (7.2, 10.8)11.7 (8.1, 13.4)10.4 (7.9, 14.0)0.030.010.030.84
PICP, ng/ml15.0+ (10.0, 34.0)127.4 (113.3, 170.2)46.8 (22.6, 98.6)106.4 (85.4, 140.4)0.0050.0060.090.043
PIIINP, ng/ml1.27+ (0.67, 3.18)3.38 (2.85, 3.61)3.29 (1.96, 4.59)3.46 (2.24, 4.97)0.580.680.490.38
PICP/PIIINP7.4+ (3.7, 8.4)35.3 (30.1, 44.4)18.4 (14.6, 25.3)31.5 (25.8, 40.1)0.070.0170.350.033
MMP-9, ng/ml540.0 (363.0, 669.0)412.5 (289.5, 687.7)277.0# (98.5, 403.5)257.0 # (152.0, 483.5)0.120.260.110.51
TIMP-1, ng/ml149.0 (133.0, 170.0)208 (172, 241)178.5 (119.5, 210.7)154 (114.7, 203.5)0.160.210.050.81
MMP-9/TIMP-13.6+ (2.3, 5.2)1.6 (1.2, 2.8)1.1 (0.6, 3.6)0.8 (0.42, 3.1)0.310.440.390.5
hsCRP, mg/lā€”2.1 (0.8, 4.9)2.5 (1.7, 5.9)3.3 (2.0, 7.3)0.410.290.310.61

+ (between control group and investigated groups); # (between control group and groups 2 and 3).